Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;86(1):101691.
doi: 10.1016/j.ando.2025.101691. Epub 2025 Jan 14.

Chapter 2: Primary Hyperparathyroidism: diagnosis

Affiliations
Free article
Review

Chapter 2: Primary Hyperparathyroidism: diagnosis

Benjamin Bouillet et al. Ann Endocrinol (Paris). 2025 Feb.
Free article

Abstract

Primary hyperparathyroidism is now predominantly an asymptomatic pathology, as blood calcium assay has become systematic. Diagnosis therefore requires screening for target organ damage when this is not already indicative of primary hyperparathyroidism. Classical clinical manifestations include bone, kidney and muscle signs, and are characterized by reversibility after parathyroid surgery. Their presence requires blood calcium assay. Non-classical manifestations include cardiovascular, digestive and neuropsychological signs, which are not known to be reversible after surgery. Positive diagnosis is biological, based on a parathyroid hormone value that is inappropriate to the blood calcium value. The typical form combines hypercalcemia, elevated parathyroid hormone and increased calciuria or calcium excretion fraction. Atypical forms combine either hypercalcemia and normal parathyroid hormone level, or normal calcemia with increased parathyroid hormone level, not necessarily secondary to another cause, such as 25(OH) vitamin D deficiency. The oral calcium loading test and the Pro-FHH score are contributive to diagnosis in atypical forms.

Keywords: Asymptomatic; Biological diagnosis; Hypercalcemia; Osteoarticular involvement; Primary hyperparathyroidism; Renal involvement.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest JPB has received honoraria as speaker, investigator or consultant for Amolyt Pharma and Ascendis Pharma. BB, CNR and VK declare that they have no competing interest.

MeSH terms

LinkOut - more resources